Aurobindo Pharma USA Secures FTC Approval for Lannett Deal Kumar Jeetendra | June 22, 2026 Aurobindo Pharma USA, Inc. a wholly owned subsidiary of the Company, today announced that it has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (“Lannett”). The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to …
Sun Pharma Acquires Innovcare Lifesciences for ₹271 Crore Kumar Jeetendra | June 22, 2026 Sun Pharmaceutical Industries, India’s biggest pharmaceutical drug maker, is buying 100% Mumbai-based Innovcare Lifesciences for an all-cash transaction worth $28.7 million. The transaction is expected to close on or before July 31, 2026. Sun Pharma Expands Indian Healthcare Portfolio with ₹271 Crore Innovcare Lifesciences Acquisition This acquisition will allow Sun Pharma to continue on its …
Alembic Gets USFDA Final Approval for Tretinoin Cream 0.05% Kumar Jeetendra | June 15, 2026 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tretinoin Cream USP, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.05%, of Bausch Health US, LLC. Tretinoin cream is …
Alembic Pharma Receives USFDA Approval for Haloperidol Tablets Kumar Jeetendra | June 5, 2026 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Haldol …
Aragen to Manufacture Renaissance Pharma’s Fast-Track mAb Kumar Jeetendra | June 3, 2026 Aragen, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has successfully tech-transferred and manufactured the first commercial-scale GMP batches of Renaissance Pharma’s lead candidate, Daretabart – a humanized monoclonal antibody targeting GD2 for high-risk neuroblastoma – in just 9 months. The anti-GD2 monoclonal antibody received Fast Track Designation from the FDA in April 2026 for …
Cipla Launches First-of-its-kind Sputum Inflammometry Lab Kumar Jeetendra | June 3, 2026 Cipla Limited today announced the launch of a first-of-its-kind Sputum Inflammometry Lab at the Breathefree Lung Wellness Center (BLWC) in Mumbai, marking the advancement of precision respiratory diagnostics and integrated respiratory care in the country. The lab was inaugurated by Dr. Parameswaran Nair, globally recognised as one of the pioneers and leading experts in the …
Alembic Pharma Wins USFDA Approval for Dapagliflozin Tablets Kumar Jeetendra | April 7, 2026 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapagliflozin Tablets, 5 mg and 10 mg. Alembic Pharmaceuticals Limited Gets USFDA Approval for Dapagliflozin Tablets The approved ANDA is therapeutically equivalent to the reference listed drug product …
Conflict to Capsules: Pharma Feels the Heat Kumar Jeetendra | March 31, 2026 The sustained tensions between Iran and the United States since 2026 have become increasingly severe, with impacts beyond military engagements, including an expansive global economic impact, and an effect on Asia’s pharmaceuticals industry, which is now one of the most impacted. The Global Economic Impact of the War The war has impacted one of the …
Alembic Pharma Gets USFDA Approval for Paroxetine ER Tablets Kumar Jeetendra | March 30, 2026 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its supplemental Abbreviated New Drug Application (sANDA) Paroxetine Extended-Release Tablets USP, 12.5 mg. The approved sANDA is therapeutically equivalent to the reference listed drug product (RLD), Paxil CR Tablets, 12.5 mg, of Apotex Inc. …
Mettler-Toledo to Showcase Product Inspection Innovations at Interpack 2026 Kumar Jeetendra | February 9, 2026 Giesen, Germany. 26 January 2026 – At Interpack 2026, Mettler-Toledo Product Inspection (Hall 11 Stand A60), a global leader in precision instruments and inspection solutions, will demonstrate how manufacturers can inspect every product with confidence, protect brands and profits, and comply with evolving regulatory requirements, under the theme “Inspect. Protect. Comply.” Visitors from the food, …
Top 10 Pharma Companies Shaping India’s Healthcare (2026) Kumar Jeetendra | January 21, 2026 India is one of the largest centers of global pharmaceutical manufacturers, who supply cost effective and high quality medicines. The majority of Indian pharmaceutical manufacturers produce and market generics, active pharmaceutical ingredients (APIs), biosimilars and specialty therapies which foster progressive and affordable healthcare. Regarding the elements of company profile market standing, production potential, research and …
Top 10 Trends Driving Lab, Pharma & Biopharma in 2026 Kumar Jeetendra | January 20, 2026 Advancements in technology, changes in regulatory frameworks, a growing emphasis on sustainable practices, and the need for innovation are reshaping the laboratory, pharmaceutical, and biopharmaceutical sectors. Through the lens of Industry Adoption, Impacts, and Relevance to the Indian and Global Markets, Microbioz India examines the trends with the highest magnitude of change. Rank 1: Automation …
